INTRODUCTION
============

Prostate cancer (PCa) is the second most frequently diagnosed cancer and the sixth leading cause of cancer death in men worldwide with an approximately 14% (903,500) of total new cancer cases and 6% (258,400) of the total cancer deaths in males in 2008 ([@B1]). In Korea, PCa is the fifth most common cancer in men, and its incidence is the most rapidly increasing of all cancers ([@B2]). PCa shows an extremely heterogeneous clinical course, ranging from indolent to aggressive, metastatic lethal disease ([@B3]). Consequently, there is a great need to accurately estimate the tumor characteristics of PCa so that appropriate treatment options can be considered. Currently, histopathological analysis (including tumor stage and grade) and serum prostate specific antigen (PSA) levels are key determinants of therapeutic decision-making. However, none of the histological criteria or bio-markers reported to date show sufficient sensitivity and specificity for detecting, monitoring, or determining the prognosis of PCa ([@B4], [@B5]). Thus, there is a critical need for methods capable of predicting oncologic outcomes and responses to therapy in PCa patients. The abnormal expression of certain genes in cancer cells is closely related to distinct aspects of tumor progression, including tumor growth, invasion, and metastasis. Proper cell division requires the precise coordination and execution of several events in the cell cycle, including centrosome duplication, DNA replication, mitotic spindle assembly, chromosome segregation, and cytokinesis ([@B6]). A failure in the execution or proper timing of any of these events could lead to chromosome segregation defects, resulting in aneuploidy or polyploidy ([@B7], [@B8], [@B9]).

Mps one binder (MOB) was originally identified in yeast as a regulator of mitotic exit and cytokinesis, and was later identified as a tumor suppressor ([@B10]). hMOB1 can bind to and activate mammalian large tumor suppressor (LATS) and nuclear Dbf2-related (NDR) kinases (LATS1, LATS2, NDR1, and 2) by targeting and activating these kinases at the plasma membrane ([@B11], [@B12]). Increased expression of LATS1 or LATS2 inhibits tumor cell growth by inducing cell cycle arrest or apoptosis ([@B10], [@B11], [@B13], [@B14], [@B15]). Recent studies show that hMOB1 is downregulated in colorectal and non-small cell lung cancers ([@B9], [@B12]). hMOB2 binds to the same domain on NDR1/2, but does not bind to LATS1/2; binding of hMOB2 to NDR1/2 kinases inhibits the phosphorylation of NDR and thereby blocks kinase activation ([@B16]). hMOB2 is classified as an inhibitor of NDR signaling, whereas hMOB1 is classified as a co-activator of the NDR/LATS signaling cascades ([@B17], [@B18]). The human MOB protein family consists of six members: hMOB1A, 1B, 2, 3A, 3B, and 3C ([@B18]). Unfortunately, although hMOB1 and 2 have been extensively studied, the biological roles and binding partners of hMOB3A/B/C are unknown ([@B18]). Recent studies revealed that all six *hMOB3B* are abundantly expressed in human prostate tissue ([@B10]), and that methylation-induced gene silencing of *hMOB3B* occurs in PCa ([@B19]). Based on previous research, we hypothesized that *hMOB3B* acts as a tumor suppressor, and that its loss of function contributes to the carcinogenesis and aggressiveness of human PCa. Here, we compared the expression levels of *hMOB3B* in normal and prostate cancer tissues to examine the contribution of this gene to prostate carcinogenesis. Also, and more importantly, we investigated the effect of *hMOB3B* on the clinicopathological characteristics of PCa in Korean men.

MATERIALS AND METHODS
=====================

Study population
----------------

This case-control study was included 137 cases of newly diagnosed PCa and 137 age-matched benign prostatic hyperplasia (BPH) controls. The study cases were recruited from patients with histologically confirmed primary adenocarcinoma of the prostate at our hospital. Controls were selected from a database of BPH patients who underwent transurethral resection of the prostate (TURP), and were one-to-one matched (as far as possible) according to age and date of blood sampling. Controls with high PSA (serum PSA levels \>2.5 ng/mL) underwent transrectal prostate biopsy before TURP to rule out the presence of cancer, and those with PSA levels \>10 ng/mL were excluded from the study. Subjects with a suspicious history of previous management for PCa or incomplete medical records were also excluded. Gleason grade and 2002 TNM stage were used as prognostic factors. Gleason grade was measured in 12-core transrectal biopsy, TURP, or radical prostatectomy specimens. Tumor stage was estimated from the radical prostatectomy specimens, or from computed tomography (CT), magnetic resonance imaging (MRI), or bone scan results.

RNA extraction and construction of cDNA
---------------------------------------

TRIzol (1 mL; Invitrogen, Carlsbad, USA) was added to BPH control and PCa tissues and homogenized in a 5 mL glass tube. The homogenate was transferred to a 1.5 mL tube and mixed with 200 µL chloroform. After incubating for 5 min at 4℃, the homogenate was centrifuged for 13 min at 13,000×g at 4℃. The upper aqueous phase was transferred to a clean tube and 500 µL isopropanol was added, followed by incubation for 60 min at 4℃. The tube was then centrifuged for 8 min at 13,000×g and 4℃. Next, the upper aqueous phase was removed, mixed with 500 µL of 75% ethanol, and centrifuged for 5 min at 13,000×g and 4℃. After the upper aqueous layer was discarded, the pellet was dried at room temperature, dissolved with diethylpyrocarbonate (DEPC)-treated water, and stored at -80℃. The quality and integrity of the RNA were confirmed by agarose gel electrophoresis and ethidium bromide staining, followed by visual examination under ultraviolet light. cDNA was then prepared from 1 µg f RNA by random priming with a First-Strand cDNA Synthesis Kit (Amersham Biosciences Europe GmbH, Freiburg, Germany) according to the manufacturer\'s protocol.

Real-time PCR
-------------

To quantify the expression of *hMOB3B*, real-time PCR was performed using a Rotor Gene 6000 instrument (Corbett Research, Mortlake, Australia). Real-time PCR assays using SYBR Premix EX Taq (TAKARA BIO INC., Otsu, Japan) were carried out in micro-reaction tubes (Corbett Research, Mortlake, Australia) using *hMOB3B* (6,528 bp) sense (5\'-GTG GCA GGA TGA TCT CAA-3\') and antisense (5\'-CGG CAC AGG ATC TTC TTG-3\') primers. The PCR reaction was performed in a final volume of 10 µL, comprising 5 µL of 2×SYBR Premix EX Taq buffer, 0.5 µL of each 5\' and 3\' primer (10 pM/µL), and 1 µL of sample cDNA. The products were purified with a QIAquick Extraction kit (QIAGEN, Hilden, Germany), quantified in a spectrometer (Perkin Elmer MBA2000, Fremont, USA), and sequenced using an automated laser fluorescence sequencer (ABI PRISM 3100 Genetic Analyzer, Foster City, USA). A known concentration of the PCR product was then 10-fold serially diluted from 100 pg/µL to 0.1 pg/µL and used to establish a standard curve. The real-time PCR conditions were as follows: 1 cycle at 96℃ for 20 sec, followed by 40 cycles of 3 sec at 96℃ for denaturation, 15 sec at 60℃ for annealing, and 15 sec at 72℃ for extension. The melting program was performed at 72-95℃, with a heating rate of 1℃ per 45 sec. Spectral data were PCatured and analyzed using Rotor Gene Real-Time Analysis Software 6.0 Build 14 (Corbett Research, Mortlake, Australia). All samples were run in triplicate. Glyceraldehyde-3-phosphate dehydrogenase (*GAPDH*) was used as an endogenous RNA reference gene. Gene expression was normalized to the expression of *GAPDH*.

Statistical analysis
--------------------

Clinical variables such as age, PSA, prostate size, and BMI were compared using the Mann-Whitney U-test. To evaluate tumor characteristics, Gleason scores were classified as ≤7 and ≥8, and the clinical stage was categorized as ≤T4 or metastatic disease (any nodal or distant metastasis). Statistical analysis was performed using SPSS 20.0 software (SPSS Inc., Chicago, IL, USA), and a *P* value \<0.05 was considered statistically significant.

Ethics statement
----------------

The study protocol of collection and analyses of all samples was reviewed and approved by the institutional review board of Chungbuk National University (IRB approved number 2006-01-001). Informed consent was obtained from each subject.

RESULTS
=======

Baseline characteristics
------------------------

[Table 1](#T1){ref-type="table"} lists the baseline clinical and pathologic characteristics of the 137 BPH controls and the 137 PCa patients. The mean age of the PCa patients and controls was 69.2 yr. The serum PSA level was higher in PCa patients than in the BPH controls (124.9±380.6 vs. 4.0±5.2; *P*\<0.001). There was no significant difference between cases and controls regarding prostate size (*P*=0.037). Among the 137 PCa patients, 72 (52.6%) underwent radical prostatectomy and the other 65 (47.4%) underwent palliative TURP. Stage and Gleason grade at diagnosis were as follows: 91 cases had localized-to-advanced disease (T2-4N0M0) and 46 (33.6%) had metastatic disease (any T, N+/M+); the Gleason score was ≤7 and ≥8 for 64 (46.7%) and 73 (53.3%) patients, respectively.

Expression levels of *hMOB3B* mRNA in normal and cancer tissues
---------------------------------------------------------------

To identify whether *hMOB3B* is involved in prostate cancer susceptibility, we compared mRNA expression levels in BPH and PCa tissues. The median *hMOB3B* mRNA expression level in PCa tissues was significantly lower (median 426.2×10^4^ copies per µg; IQR, 197.6-637.0) than that in BPH tissues (median 1,108.5×10^4^ copies per µg; IQR, 797.0-1,428.0) (*P*\<0.001, [Table 1](#T1){ref-type="table"} and [Fig. 1](#F1){ref-type="fig"}). According to receiver operating curve (ROC) statistical analysis, the sensitivity of *hMOB3B* expression for diagnosing prostate cancer was 84.7%, with a specificity of 86% at a reference value of 737.5×10^4^ copies per µg (AUC, 0.910; 95% CI, 0.869-0.941; *P*\<0.001) ([Fig. 2](#F2){ref-type="fig"}).

Relationship between *hMOB3B* mRNA expression levels and clinicopathologic features
-----------------------------------------------------------------------------------

*hMOB3B* mRNA expression was significantly lower in patients with elevated PSA levels (≥10 ng/mL) than in those with low PSA levels (*P*=0.001). In addition, *hMOB3B* expression was significantly lower in cancer tissue specimens from patients with a higher Gleason score (≥8) and metastatic disease (any T, N+/M+) than in samples from those with a lower Gleason score (≤7) and non-metastatic disease (T2-4N0M0) (each *P*\<0.001) ([Table 2](#T2){ref-type="table"} and [Fig. 3A-C](#F3){ref-type="fig"}).

DISCUSSION
==========

In this study, we identified a relationship between *hMOB3B* expression and an increased risk of PCa. In addition, *hMOB3B* expression was closely associated with clinicopathologic features in patients with PCa. MOB proteins are crucial regulators of NDR family kinases and are conserved from yeast to humans. Members of the MOB protein family regulate mitosis, cell proliferation, apoptosis, centrosome biology, and morphological changes ([@B12], [@B20]). Signal transduction cascades control essential biological processes such as cell division, morphogenesis, cell growth, and controlled cell death/apoptosis ([@B21]). The vast majority of signaling cascades transmit extra- and intracellular inputs via protein kinases ([@B11], [@B22]). A conserved property of MOB proteins is its association with and activation of NDR (nuclear-Dbf2-related) kinases belonging to the AGC family, which includes PKA, PKG, and PKC ([@B18], [@B23]). Human cells express four related NDR kinases: NDR1 (also known as serine/threonine kinase 38 or STK38), NDR2 (or STK38L), LATS1 (large tumor suppressor-1), and LATS2 ([@B11], [@B24], [@B25], [@B26]). Originally, the biological roles of MOB proteins were investigated mainly using budding and fission yeast. In budding and fission yeast, MOB proteins are expressed from two independent genes. Mob1p regulates both the mitotic exit network in budding yeast and the septation initiation network in fission yeast by binding to and activating Dbf2p and Sid2p kinases, respectively ([@B11], [@B12], [@B25], [@B27]). In addition, Mob1p also plays a major role in modulating cytokinesis, the last stage of the cell cycle ([@B28]). MOB2 regulates cell polarity and daughter-specific gene expression programs during the yeast cell cycle by modulating Cbk1p and Orb6p kinases ([@B29]). The human MOB protein family consists of six distinct members (hMOB1A, 1B, 2, 3A, 3B, and 3C), with hMOB1A/B being the best studied due to their putative tumor suppressive functions, which are mediated through regulation of the NDR/LATS kinases ([@B10], [@B11], [@B18], [@B24]). The biological features of the other hMOBs are largely unknown. hMOB1A binds to and activates human NDR1/2 kinases by stimulating autophosphorylation of the activation segment. Similarly, hMOB1A binds to and activates LATS1 and 2 ([@B11], [@B18], [@B24]). By contrast, hMOB2 binds to NDR1 and NDR2, but not to LATS1 ([@B16]). hMOB3A/B/C do not associate with any NDR/LATS kinases, and the binding partners of hMOB3A/B/C are currently unknown. Recently, a study by Haldrup et al. ([@B16]) reported that hypermethylation of six novel genes, *AOX1*, *C1orf114*, *GAS6*, *HAPLN3*, *KLF8*, and *MOB3B*, was highly cancer specific. Although we did not measure the correlation between *hMOB3B* methylation and *hMOB3B* expression levels, our data support methylation-induced gene silencing of *hMOB3B*.

A possible limitation of our study is that we did not determine the levels of *hMOB3B* protein, for example, by Western blotting or immunohistochemical staining. Second, we could not evaluate the prognostic value of hMOB3 due to relatively small sample size and inconsistent treatment modalities. Most importantly, the physiological binding partners and functions of the hMOB3 proteins remain undefined. Thus, further research is needed to identify physiological binding partners and to confirm the prognostic value of hMOB3 in PCa.

In conclusion, low levels of *hMOB3B* are closely associated with aggressive clinicopathologic features of PCa. Our results suggest a functional role for *hMOB3B* as a tumor suppressor in human PCa.
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###### Clinicopathologic characteristics of prostate cancer patients and BPH controls

![](jkms-30-937-i001)

  Characteristics                                            BPH                       PCa                   *P* value
  ---------------------------------------------------------- ------------------------- --------------------- -----------
  No.                                                        137                       137                   
  Age (yr; range)                                            69.2 (46-85)              69.2 (48-86)          0.994
  PSA±SD (ng/mL)                                             4.0±5.2                   124.9±380.6           \<0.001
  Prostate size (gram)                                       38.8±23.0                 41.3±22.2             0.387
  Operation (%)                                                                                              
   TURP                                                      137 (100)                 65 (47.4)             
   Radical prostatectomy                                                               72 (52.6)             
  Gleason score, No. (%)                                                                                     
   ≤7                                                        64 (46.7)                                       
   ≥8                                                        73 (53.3)                                       
  Stage (%)                                                                                                  
   T1-4N0M0                                                  91 (66.4)                                       
   Metastatic (any T N+/M+)                                  46 (33.6)                                       
  *hMOB3B* expression, median (IQR; × 10^4^ copies per µg)   1,108.5 (797.0-1,428.0)   426.2 (197.6-637.0)   \<0.001

*P* values were obtained from the Mann-Whitney U-test. BPH, benign prostatic hyperplasia; PCa, prostate cancer; IQR, interquartile range; SD, standard deviation; TURP, transurethral resection of the prostate.

###### *hMOB3B* mRNA expression levels according to PSA, Gleason score, and metastasis status in prostate cancer patients

![](jkms-30-937-i002)

  Characteristics   No   *hMOB3B* expression, median (IQR; × 10^4^ copies/µg)   *P* value
  ----------------- ---- ------------------------------------------------------ -----------
  PSA                                                                           0.001
   ≤10              38   545.2 (382.9-730.3)                                    
   \>10             99   349.6 (123.6-569.9)                                    
  Gleason score                                                                 \<0.001
   ≤7               64   509.8 (300.6-687.3)                                    
   ≥8               73   320.9 (96.9-545.2)                                     
  Stage                                                                         \<0.001
   T1-4N0M0         91   491.1 (299.2-716.4)                                    
   any T N+/M+      46   243.8 (96.4-448.4)                                     

*P* values were obtained from the Mann-Whitney U-test. IQR, interquartile range; PSA, prostate specific antigen; SD, standard deviation.
